

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT

040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

May 5, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Earnings Call Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the schedule of Q4 FY 2025 Earnings Call details.

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland Laboratories Limited's Q4FY25 Results Conference Call

Neuland Laboratories Limited will announce its results for the fourth quarter and financial year ended March 31, 2025 on May 15, 2025.

The results will also be made available on the website of the Company, www.neulandlabs.com

Following the announcement, the management of the Company will host an Earnings Call on May 15, 2025 at 17:00 hrs.

The details of the earnings call are:

Date:
May 15, 2025

Time:
17:00 Hrs (IST)

For Diamond Pass Registration Please Click Here:

Diamond Pass

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANLAB)

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 980 Regulatory filings across the US (72 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com

For more queries please contact:

Neuland: ir@neulandlabs.com

Ravi Udeshi: ravi.udeshi@in.ey.com